))
The Science and Art of De-risking Cancer Drug Development | Talking Precision Medicine #35
Manage episode 412096769 series 3103485
Content provided by Genialis. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Genialis or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode Genialis CEO Rafael Rosengarten sat down with Dr. Carolina Haefliger, head of translational medicine at Debiopharm, the privately held Swiss biopharma company focused on oncology drug development. They talked about de-risking promising new cancer drugs, and what it takes from the science to the team to the technologies.
Episode 35 links:
39 episodes
Share
